Argenx profit surges 116% as VYVGART sales hit $1.3B in record Q1

Argenx (NASDAQ:ARGX) delivered a powerful start to 2026, reporting first-quarter financial results that demonstrate the accelerating commercial scale of its flagship FcRn blocker, VYVGART.

The Amsterdam-based biotech reported global product net sales of $1.3 billion for the quarter ended March 31, 2026, representing a 63% increase over the $790 million recorded in the same period last year.

The company’s path to sustained profitability reached a new milestone as net profit for the period climbed to $366 million, a 116% surge year-over-year.

Operating profit stood at $394 million, reflecting strong operational leverage as the company expands its footprint in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) while maintaining a disciplined cost structure.

The quarter’s results arrive just days before a pivotal regulatory milestone.

The U.S. Food and Drug Administration (FDA) has set a PDUFA target action date of May 10, 2026, for argenx’s supplemental Biologics License Application (sBLA) for VYVGART in seronegative gMG.

If approved, efgartigimod would become the first targeted therapy for this underserved patient population, which comprises approximately 15% to 20% of the total gMG market.

Argenx is also moving aggressively to fulfill its "Vision 2030" goals.

The company confirmed it is on track to have 10 clinical-stage molecules in development by the end of 2026.

This includes advancing empasiprubart (C2 inhibitor) and adimanebart (MuSK agonist) through registrational studies, alongside exploring new indications such as ocular MG, where positive Phase 3 results were recently presented.

Meanwhile, Argenx ended the first quarter with a formidable balance sheet, reporting $4.9 billion in cash and current financial assets.

This liquidity provides the firm with significant runway to fund its broad-based R&D efforts and the potential commercial launch of VYVGART in new indications globally.